ImpediMed Limited (IPDQF)
- Previous Close
0.0200 - Open
0.0200 - Bid 0.0194 x --
- Ask 0.0345 x --
- Day's Range
0.0200 - 0.0200 - 52 Week Range
0.0190 - 0.0684 - Volume
15,499 - Avg. Volume
15,085 - Market Cap (intraday)
44.27M - Beta (5Y Monthly) 2.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Jul 27, 2025 - Jul 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company was incorporated in 1999 and is headquartered in Carlsbad, California.
www.impedimed.comRecent News: IPDQF
View More
Performance Overview: IPDQF
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPDQF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPDQF
View MoreValuation Measures
Market Cap
44.27M
Enterprise Value
33.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.29
Price/Book (mrq)
1.85
Enterprise Value/Revenue
4.62
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-183.82%
Return on Assets (ttm)
-29.71%
Return on Equity (ttm)
-50.94%
Revenue (ttm)
11.54M
Net Income Avi to Common (ttm)
-21.22M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
17.69M
Total Debt/Equity (mrq)
3.24%
Levered Free Cash Flow (ttm)
-14.22M